Brokerages expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to announce $103.83 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Amphastar Pharmaceuticals’ earnings, with estimates ranging from $101.90 million to $106.30 million. Amphastar Pharmaceuticals reported sales of $83.43 million during the same quarter last year, which indicates a positive year over year growth rate of 24.5%. The firm is expected to issue its next quarterly earnings report on Friday, November 5th.
According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year sales of $418.78 million for the current financial year, with estimates ranging from $410.40 million to $431.13 million. For the next financial year, analysts forecast that the business will report sales of $472.93 million, with estimates ranging from $452.80 million to $502.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Sunday, August 8th. The company reported $0.21 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.21. Amphastar Pharmaceuticals had a return on equity of 8.01% and a net margin of 2.72%.
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,000 shares of the stock in a transaction dated Wednesday, July 7th. The stock was sold at an average price of $20.37, for a total value of $203,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Rong Zhou sold 5,187 shares of the stock in a transaction dated Tuesday, July 20th. The shares were sold at an average price of $20.57, for a total value of $106,696.59. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,711 shares of company stock valued at $1,066,412. 28.40% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. Captrust Financial Advisors increased its stake in shares of Amphastar Pharmaceuticals by 1,889.3% in the first quarter. Captrust Financial Advisors now owns 1,492 shares of the company’s stock valued at $27,000 after buying an additional 1,417 shares during the period. FORA Capital LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at about $27,000. Quantbot Technologies LP increased its stake in shares of Amphastar Pharmaceuticals by 866.7% in the first quarter. Quantbot Technologies LP now owns 2,900 shares of the company’s stock valued at $53,000 after buying an additional 2,600 shares during the period. Ensign Peak Advisors Inc acquired a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $59,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at about $70,000. 56.53% of the stock is owned by institutional investors.
Shares of NASDAQ:AMPH traded up $0.04 during trading on Friday, reaching $18.02. 741 shares of the company traded hands, compared to its average volume of 199,354. The company’s 50 day moving average is $19.75 and its two-hundred day moving average is $19.09. The firm has a market capitalization of $865.54 million, a PE ratio of 85.62 and a beta of 0.74. The company has a quick ratio of 1.71, a current ratio of 2.50 and a debt-to-equity ratio of 0.07. Amphastar Pharmaceuticals has a 52 week low of $16.91 and a 52 week high of $21.63.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.
See Also: What factors cause inflation to rise?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.